CI

At a glance

ClinicalIndex Comparison Record
Phase 4Active· 54 target
Drug / intervention
Pfizer-BioNTech mRNA COVID-19 vaccine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07287137
NCT07287137Phase 4ActiveOn Track
CompareCT.gov

IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Henry M. Jackson Foundation for the Advancement of Military Medicine·interventional·Posted Dec 17, 2025·Updated May 4, 2026

In Brief

A Phase 4 clinical trial evaluating Pfizer-BioNTech mRNA COVID-19 vaccine and Novavax recombinant protein vaccine for COVID -19 and 7 related conditions. Active but no longer recruiting, targeting 54 participants across 1 site.

Detailed Summary

CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention, Food and Drug Administration (FDA)

Timeline

Phase 4Active
20262027
First PostedDec 17, 2025
Enrollment StartNov 12, 2025
Primary CompletionSep 1, 2027
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7 months agoPrimary completion in 1.2 years

Interventions

Pfizer-BioNTech mRNA COVID-19 vaccinedrug

COVID-19 Vaccine, mRNA

Novavax recombinant protein vaccinedrug

Recombinant protein vaccine